NCT05818072 is a NA clinical trial of One biopsy in Barrett's Esophagus, sponsored by E-DA Hospital.

Who is sponsoring NCT05818072?

NCT05818072 is sponsored by E-DA Hospital.

What drugs are being tested in NCT05818072?

Interventions in NCT05818072: One biopsy, Three biopsy, Seattle protocol, Endoscopy.

What condition does NCT05818072 study?

NCT05818072 studies Barrett's Esophagus, Intestinal Metaplasia.

Is NCT05818072 still recruiting?

NCT05818072 is currently recruiting now. Last updated 11 May 2023.

Last reviewed 2023-05-11 · How we verify

NCT05818072

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Prevalence, Risk Factors and Optimal Biopsy Protocol of BE

Recruiting now NA Last updated 11 May 2023

What this trial tests

NA trial testing One biopsy in Barrett's Esophagus in 165 participants. Currently enrolling.

Timeline

13 March 2023

Primary endpoint
31 December 2025

31 December 2026

Quick facts

Lead sponsor	E-DA Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	165
Start date	13 March 2023
Primary completion	31 December 2025
Estimated completion	31 December 2026
Sites	1 location across Taiwan

Drugs / interventions tested

One biopsy
Three biopsy
Seattle protocol
Endoscopy

Conditions studied

Barrett's Esophagus — all drugs for Barrett's Esophagus →
Intestinal Metaplasia — all drugs for Intestinal Metaplasia →

Sponsor

E-DA Hospital

Who can join

20 and older, any sex, with Barrett's Esophagus or Intestinal Metaplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Detections of goblet cells and dysplasia are crucial for diagnosis and determining the surveillance program of Barrett's esophagus (BE). However, the optimal biopsy numbers and their yield rates of intestinal metaplasia (IM) and dysplasia are still uncertain, especially in Asia. The aim of this study was to determine the optimal biopsy protocol of BE.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Barrett's Esophagus

Currently open trials in the same condition.

NCT06748911 — Navicam for Detection of Barrett's Esophagus · NA · recruiting
NCT00590239 — Barrett's Esophagus Related Neoplasia (BERN) Project · recruiting
NCT00288119 — Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma · recruiting

Other E-DA Hospital trials

Trials by the same sponsor.

NCT03848260 — A Real-Time Magnetic Device Prototype for Temporary Management of Paralytic Lagophthalmos · NA · suspended
NCT06482411 — Risk Factors Affect Weight Loss Outcomes After Treatment. · completed
NCT05863208 — Artificial Intelligence-assisted Colonoscopy With or Without Endocuff Vision · NA · recruiting
NCT06460402 — Ice Therapy and Warm Baths for Hemorrhoidectomy Wound Care · NA · enrolling by invitation
NCT06420388 — 2% Lidocaine Gel in Reducing Postoperative Pain Following Haemorrhoidectomy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05818072 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by E-DA Hospital
Last refreshed: 11 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05818072.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing